How did Synthetic Biologics, Inc. (NYSE American: SYN) climb during premarket?
Clinical-stage company Synthetic Biologics, Inc. (NYSE American: SYN) develops therapeutics for gastrointestinal diseases. Its lead product candidates include SYN-004 that has completed Phase II clinical studies designed to degrade commonly used intravenous beta-lactam antibiotics that have been in use for years. Recent Performance In the recent session Company’s stock finished up 30.57% to $0.50. During […]